Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$682.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$674.85M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$688.55M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$686.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$688.40M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$691.64M
Gross Margin
79.28%
TTM Avg
89.64%
3Y Avg
94.82%
5Y Avg
-12.16%
Market Cap
$666.85M
Gross Margin
78.85%
TTM Avg
82.67%
3Y Avg
82.58%
5Y Avg
83.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $682.79M | 0.00% | 0.00% | 0.00% | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $674.85M | 0.00% | 0.00% | 25.00% | 33.33% |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.55M | 0.00% | 0.00% | 0.00% | 0.00% |
| Verastem, Inc. (VSTM)vs › | $685.85M | 86.69% | 91.43% | 70.72% | 74.12% |
| Annexon, Inc. (ANNX)vs › | $665.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $686.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.40M | -16.57% | 15.14% | 17.91% | 27.64% |
| Wave Life Sciences Ltd. (WVE)vs › | $691.64M | 79.28% | 89.64% | 94.82% | -12.16% |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 78.85% | 82.67% | 82.58% | 83.02% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $658.16M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
